Kerri-Ann Millar - 21 Aug 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/Kerri-Ann Millar by Colin Sanderock, attorney-in-fact
Issuer symbol: CUE
Transactions as of: 21 Aug 2022
Net transactions value: -$8,625
Form type: 4
Filing time: 23 Aug 2022, 16:03:38 UTC
Previous filing: 29 Mar 2022
Next filing: 21 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Options Exercise		+6,667	+64%		17,139	21 Aug 2022	Direct	F1
transaction	CUE	Common Stock	Tax liability	$8,625	-2,828	-17%	$3.05	14,311	22 Aug 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Restricted Stock Units	Options Exercise	$0	-6,667	-100%	$0.000000^*	0	21 Aug 2022	Common Stock	6,667		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award
F2	Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3	Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020.